Urilax200 mg

Urilax is indicated for the symptomatic relief of urinary tract symptoms associated with lower urinary tract conditions. This is an FDA-approved, established indication.

• Dysuria (painful urination)
• Urgency and increased frequency of urination
• Nocturia (excessive urination at night)
• Suprapubic pain
• Urinary incontinence associated with detrusor instability

These symptoms may occur in association with cystitis, prostatitis, urethritis, and urethrocystitis.

Important limitation: Urilax provides symptomatic relief only; it does not treat the underlying infection or cause of the urinary tract condition. When an infection is present, Urilax should be used as an adjunct alongside appropriate antimicrobial or other definitive therapy directed at the underlying cause, not as a substitute for it.

Each tablet contains Flavoxate Hydrochloride as the active ingredient, commonly available in strengths of 100 mg and 200 mg.

Urilax is a synthetic anticholinergic (antimuscarinic) and direct-acting smooth muscle antispasmodic agent. It acts on the smooth muscle of the urinary tract to relieve spasm, thereby reducing the associated symptoms of urgency, frequency, nocturia, and dysuria. Urilax is administered orally, usually as a tablet, and is used for short-term symptomatic management rather than as a cure for the underlying urinary tract disorder.

Urilax belongs to the class of urinary antispasmodics / anticholinergic (antimuscarinic) agents used for genitourinary smooth muscle relaxation.

Flavoxate Hydrochloride exerts a direct antispasmodic action on smooth muscle of the urinary tract, counteracting spasm. It also has anticholinergic (antimuscarinic), local anesthetic, and analgesic properties, along with mild calcium channel-blocking activity. Through these combined mechanisms, Flavoxate Hydrochloride relaxes detrusor and other urinary tract smooth muscle, increases bladder capacity, and reduces the frequency of uninhibited bladder contractions, thereby relieving symptoms such as urgency, frequency, nocturia, dysuria, and suprapubic discomfort. It does not have antimicrobial activity and does not treat the underlying cause of urinary tract infection or inflammation.

Urilax tablets are taken orally, swallowed whole with a glass of water, with or without food, at evenly spaced intervals as directed by the physician.

Formal drug-interaction studies with Urilax are limited, but as an anticholinergic agent, clinically relevant interactions are anticipated based on its pharmacologic class:

• Other anticholinergic/antimuscarinic drugs (e.g., certain antihistamines, tricyclic antidepressants, antipsychotics, other antispasmodics): concurrent use with Urilax may have additive anticholinergic effects such as dry mouth, blurred vision, constipation, urinary retention, and confusion.
• CNS depressants (e.g., sedatives, alcohol): may add to the drowsiness that Urilax can cause.

Inform your physician of all medicines being taken before starting Urilax.

Adverse effects associated with Urilax are generally related to its anticholinergic activity and are usually mild and reversible on dose reduction or discontinuation.

• Common: dry mouth, blurred vision, dizziness, nausea, drowsiness, headache, nervousness
• Less common: vomiting, constipation (particularly at higher doses), tachycardia, palpitations, increased ocular tension, urticaria/skin rash
• Rare: abdominal pain or discomfort, difficulty concentrating, mental confusion (especially in elderly patients), eosinophilia, leukopenia

Seek medical advice if any side effect is severe or persistent.

Data on the use of Urilax in human pregnancy are limited. Animal reproduction studies have not shown evidence of impaired fertility or fetal harm, but this does not guarantee safety in humans. Urilax should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use.

It is not known whether Urilax is excreted in human breast milk. Caution should be exercised, and a physician should be consulted, before using Urilax during breastfeeding.

Urilax should be used with caution in the following situations:

• Glaucoma: Use cautiously in patients with suspected or diagnosed glaucoma, particularly narrow-angle (angle-closure) glaucoma, as anticholinergic activity may increase intraocular pressure.
• Elderly patients: Older adults may be more sensitive to the anticholinergic effects of Urilax, including confusion, drowsiness, and blurred vision (see Use in Special Populations).
• Hazardous activities: Urilax may cause drowsiness or blurred vision; patients should use caution when driving or operating machinery until they know how the medicine affects them.
• Underlying infection: Urilax treats symptoms only; a persistent fever or worsening urinary symptoms should prompt medical evaluation for an underlying infection requiring specific treatment.

Symptoms of overdose with Urilax may include exaggerated anticholinergic effects such as severe dry mouth, blurred vision, marked drowsiness, confusion, tachycardia, and, rarely, mental disturbances. In case of a suspected overdose of Urilax, seek immediate medical attention or contact a poison control center/emergency services; do not attempt to manage overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric use: Urilax is not recommended for children 12 years of age and under, as safety and efficacy have not been established in this age group.

Elderly: Elderly patients may be more susceptible to anticholinergic adverse effects of Urilax, such as confusion, drowsiness, and visual disturbances; use with caution and monitor closely.

Renal/hepatic impairment: Specific dose-adjustment data are not well established; use with caution and physician supervision in patients with significant renal or hepatic impairment.

Duration of treatment with Urilax should be individualized by the treating physician based on symptom response, generally continued only as long as symptoms persist, with dose reduction as symptoms improve. Prolonged use without periodic medical review is not recommended.

Anticholinergic (antimuscarinic) agent; urinary antispasmodic.

Flavoxate Hydrochloride acts directly on urinary tract smooth muscle to relieve spasm and also exerts anticholinergic, local anesthetic, and mild calcium channel-blocking effects, resulting in relaxation of the detrusor muscle, increased bladder capacity, and relief of urgency, frequency, nocturia, and dysuria.

Urilax is not recommended for use in children 12 years of age and under because safety and efficacy have not been established in this population. Use in adolescents over 12 years follows adult dosing recommendations under medical supervision.